Trial Profile
Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Jan 2019 Status changed from active, no longer recruiting to completed.
- 12 Dec 2018 This trial has been completed in Poland (end date: 2018-09-05)
- 20 Oct 2018 This trial has been completed in France (end date: 2018-09-07)